Results 211 to 220 of about 72,228 (243)

Case Report: JAK inhibitors for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis with spontaneous pneumomediastinum. [PDF]

Front Med (Lausanne)
Yang X, Cui X, Li X.
europepmc   +1 more source

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry. [PDF]

RMD Open
Miyazaki Y, Nakayamada S, Tanaka H, Hanami K, Fukuyo S, Kubo S, Yamaguchi A, Miyagawa I, Satoh-Kanda Y, Todoroki Y, Inoue Y, Ueno M, Tanaka Y.   +12 more
europepmc   +1 more source

Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.

JAMA Netw Open
Solitano V, Ahuja D, Lee HH, Gaikwad R, Yeh KH, Facciorusso A, Singh AG, Ma C, Ananthakrishnan AN, Yuan Y, Singh N, Jairath V, Singh S.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

JAK inhibitors for rheumatoid arthritis

Expert Opinion on Investigational Drugs, 2023
JAK (Janus kinase) is a type of non-receptor tyrosine kinase that includes JAK1, JAK2, JAK3, and Tyk2. Currently, there are five JAK inhibitors approved for treating rheumatoid arthritis. These inhibitors vary in their selectivity for different JAK isoforms.This review outlines the mode of actions and the results of Phase III trials of the JAK ...
Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka   +2 more
openaire   +2 more sources

Selective JAK Inhibitors

Future Medicinal Chemistry, 2014
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform.
Brian W, Dymock, Eugene Guorong, Yang, Yuyi, Chu-Farseeva, Lianbin, Yao   +3 more
openaire   +2 more sources

An Update on JAK Inhibitors

Current Medicinal Chemistry, 2019
Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2. JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway.
Musumeci, Francesca, Greco, Chiara, Giacchello, Ilaria, Fallacara, Anna Lucia, Ibrahim, Munjed M, Grossi, Giancarlo, Brullo, Chiara, Schenone, Silvia   +7 more
openaire   +3 more sources

JAK Protein Kinase Inhibitors

Drug News & Perspectives, 2005
In humans, the Janus protein tyrosine kinase family (JAKs) contains four members: JAK1, JAK2, JAK3 and TYK2. JAKs phosphorylate signal transducers and activators of transcription (STATs) simultaneously with other phosphorylations required for activation, and there are several cellular mechanisms in place to inhibit JAK/STAT signaling. That one might be
openaire   +2 more sources

[JAK inhibitor].

Nihon rinsho. Japanese journal of clinical medicine, 2013
Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment ...
Kunihiro, Yamaoka, Yoshiya, Tanaka
openaire   +1 more source

JAK Inhibitor in CALR-Mutant Myelofibrosis

New England Journal of Medicine, 2014
na
PASSAMONTI, FRANCESCO, Caramazza, D., Maffioli, M.   +2 more
openaire   +6 more sources